Clinical Study
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Table 3
Response to treatment.
| Enrolled patients | 43 |
| Biochemical response | | PSA decline ≥50% | 27 (62.8%) | Stable disease | 9 (20.9%) | Progressive disease | 7 (16.3%) |
| Objective response | | Partial remission | 8/17 (47.1%) | Stable disease | 7/17 (41.1%) | Progressive disease | 2/17 (11.8%) |
| Palliative response | 31 (72.1%) |
|
|